ArticlemSystems
Metabolic Responses to Polymyxin Treatment in
Article in mSystems. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Article
- Transcriptome-constrained genome-scale metabolic modeling reveals central carbon and amino acid metabolic reprogramming underlying colistin-sulbactam synergy inAntimicrobial agents and chemotherapy · 2026Article
- Screening of exogenous nutrients for pathogenic bacteria and development of highly active bactericides.mSystems · 2026Article
- Metabolic and genotypic characterization of meropenem-susceptible and meropenem-resistantTurkish journal of medical sciences · 2025Article
- Metabolic profiling unveils enhanced antibacterial synergy of polymyxin B and teixobactin against multi-drug resistant Acinetobacter baumannii.Scientific reports · 2024Article
- Deciphering Antibiotic-Targeted Metabolic Pathways inLife (Basel, Switzerland) · 2024Article
- Exploring the metabolic profile of A. baumannii for antimicrobial development using genome-scale modeling.PLoS pathogens · 2024Article
- Reconstruction and Analysis of a Genome-Scale Metabolic Model ofInternational journal of molecular sciences · 2024Article
- Arginine catabolism is essential to polymyxin dependence in Acinetobacter baumannii.Cell reports · 2024Article
- Genome-scale model ofMicrobiology spectrum · 2024Article
- Upregulated Palmitoleate and Oleate Production inMolecules (Basel, Switzerland) · 2024Article
- Polymyxins: recent advances and challenges.Frontiers in pharmacology · 2024Review
- Article
- Acinetobacter Metabolism in Infection and Antimicrobial Resistance.Infection and immunity · 2023Review
- Understanding Antimicrobial Resistance Using Genome-Scale Metabolic Modeling.Antibiotics (Basel, Switzerland) · 2023Review
- Antibiotic Resistance Diagnosis in ESKAPE Pathogens-A Review on Proteomic Perspective.Diagnostics (Basel, Switzerland) · 2023Review
- Metabolomics revealed mechanism for the synergistic effect of sulbactam, polymyxin-B and amikacin combination againstFrontiers in microbiology · 2023Article
- Isotopic Tracer for Absolute Quantification of Metabolites of the Pentose Phosphate Pathway in Bacteria.Metabolites · 2022Review
- Genome-scale metabolic modeling in antimicrobial pharmacology.Engineering microbiology · 2022Review
- Evolutionarily stable gene clusters shed light on the common grounds of pathogenicity in the Acinetobacter calcoaceticus-baumannii complex.PLoS genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Multidrug-resistant (MDR) Acinetobacter baumannii has emerged as a very problematic pathogen over the past decades, with a high incidence in nosocomial infections. Discovered in the late 1940s but abandoned in the 1970s, polymyxins (i.e., polymyxin B and colistin) have been revived as the last-line therapy against Gram-negative "superbugs," including MDR A. baumannii. Worryingly, resistance to polymyxins in A. baumannii has been increasingly reported, urging the development of novel antimicrobial therapies to rescue this last-line class of antibiotics. In the present study, we integrated genome-scale metabolic modeling with multiomics data to elucidate the mechanisms of cellular responses to colistin treatment in A. baumannii. A genome-scale metabolic model,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.